12 citations
,
November 2023 in “Skin Appendage Disorders” JAK inhibitors might help treat Lichen Planopilaris, but more research is needed.
January 2025 in “The Egyptian Journal of Hospital Medicine” Baricitinib is effective and safe for treating localized vitiligo, alone or with topical tacrolimus.
September 2022 in “Journal of The American Academy of Dermatology” Baricitinib was effective in regrowing eyebrow and eyelash hair in patients with severe alopecia areata.
169 citations
,
September 2002 in “British journal of dermatology/British journal of dermatology, Supplement” ZD1839 (Iressa) causes skin and hair side effects, treatable with tretinoin cream and minocycline.
4 citations
,
October 2024 in “Journal of the American Academy of Dermatology” Abrocitinib may help treat alopecia areata effectively with mild side effects.
4 citations
,
January 2022 in “Dermatologic Therapy” Tofacitinib was found to be a safe and effective treatment for hair regrowth in patients with alopecia areata.
January 2022 in “Dermatology Review” Higher IL-31 levels are linked to worse itching in chronic kidney disease patients.
14 citations
,
November 2016 in “Annals of Internal Medicine” Tofacitinib, an arthritis drug, helped hair growth in alopecia universalis but long-term safety needs more research.
20 citations
,
June 2007 in “Recent Patents on Endocrine, Metabolic & Immune Drug Discovery” Certain inhibitors can potentially treat prostate cancer and other hormone-dependent conditions by controlling sex hormone levels in cells.
1 citations
,
September 2022 in “BioNanoScience” Tofacitinib can help hair grow back in alopecia patients but hair loss might return if the dose is lowered.
Baricitinib is effective for Alopecia Areata but requires careful patient history evaluation.
January 2026 in “Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna)” Baricitinib effectively promotes hair regrowth and improves well-being in severe alopecia areata patients.
November 2020 in “Journal of The American Academy of Dermatology” Oral JAK inhibitors help regrow hair in alopecia patients.
3 citations
,
April 2024 in “International Journal of Women’s Dermatology” Access to JAK inhibitor therapy for alopecia areata patients is difficult, especially for racial minorities.
Tofacitinib and low-dose IL-2 may help maintain hair regrowth in alopecia areata without ongoing treatment.
March 2026 in “Mendeley Data” Janus kinase inhibitors help hair regrowth in kids with alopecia areata but need more safety research.
54 citations
,
February 1994 in “Journal of Investigative Dermatology” September 2025 in “Asian journal of pediatric dermatology.” Abrocitinib helped a 14-year-old girl with severe alopecia areata regrow her hair significantly.
1 citations
,
January 2021 in “Skin appendage disorders” A woman with alopecia regrew her hair after taking a higher dose of tocilizumab.
1 citations
,
September 2022 in “Journal of The American Academy of Dermatology” Baricitinib helps grow eyebrows and eyelashes in severe alopecia areata patients.
2 citations
,
November 2025 in “Journal of the American Academy of Dermatology” Deuruxolitinib effectively regrows hair in adults with alopecia areata and is well tolerated.
11 citations
,
August 2021 in “Stem Cell Research & Therapy” Pimecrolimus reduces the effectiveness of stem cell therapy for atopic dermatitis.
1 citations
,
April 2017 in “Journal of Investigative Dermatology” Tofacitinib may slow hair loss in scarring alopecias but is unlikely to regrow significant hair.
September 2025 in “Chinese Journal of Chromatography” A new method accurately detects illegal JAK inhibitors in hair loss cosmetics.
1 citations
,
May 2024 in “Pediatric Blood & Cancer” Trametinib can effectively treat severe kaposiform lymphangiomatosis when other treatments fail.
December 2025 in “PubMed” Baricitinib is effective and safe for treating severe alopecia areata.
March 2025 in “NATIONS UNIVERSITY INTERNATIONAL JOURNAL OF MULTI-DISCIPLINARY STUDIES” Baricitinib effectively improved skin and hair conditions in a patient with alopecia areata and atopic dermatitis.
20 citations
,
March 2023 in “American Journal of Clinical Dermatology” Baricitinib improved severe hair loss in adults over 52 weeks and was safe to use.
39 citations
,
April 2016 in “Case Reports in Dermatology” Tofacitinib temporarily regrew hair in a man with alopecia, but its effects didn't last.
7 citations
,
March 2021 in “Journal of the American Academy of Dermatology” Tofacitinib can regrow hair in alopecia areata patients, but some may experience flares during treatment.